Navigation Links
Generics Analysis: Key Patent Case Reviews

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Generics Analysis: Key Patent Case Reviews

Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.Detailed analysis of the likely date of generic entry for Cymbalta and RevlimidAnalysis of both products' position in their companies total prescription pharma portfolioCelgene is heavily dependent upon the performance of Revlimid (lenalidomide). The product generated $3.2bn in 2011, or 68.3% of the company's total sales.The only generic version submitted so far in the US is from Natco and partner Watson. A 30-month stay runs until December 2013 and the companies have been sued for infringement of 14 patents covering Revlimid, which expire across 2016–27.In 2012 and 2013, Cymbalta is forecast to account for 17.5% of Eli Lilly's total five major EU market sales. As such, generic launch timing will have a significant impact.Gain clarity on when Cymbalta and Revlimid are likely to face generic competitionAssess the threat to Eli Lilly and Celgene of these products' genericization



•Cymbalta (duloxetine; Eli Lilly) - EU launch of generic Cymbalta from August 2014

•Revlimid (lenalidomide; Celgene) - Natco sued for infringement of 14 patents



•Exchange rates



•Table: Cymbalta: patent protection and exclusivity in Europe

•Table: Revlimid: patent protection and exclusivity in the US

•Table: Exchange rates, 2012



•Figure: Cymbalta/Xeristar and Eli Lilly total five major EU market sales, 2002–17

•Figure: Revlimid and total Celgene sales, 2002–17

•Figure: US patent and exclusivity timeline relating to Revlimid

•Figure: Chemical structure of lenalidomide


Companies Mentioned

Devoteam SA, Hutchison 3G UK Limited


To order this report:

Drug_and_Medication Industry: Generics Analysis: Key Patent Case Reviews

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
3. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
4. Branded Generics in South East Asia: Current and Future Opportunities
5. Essential Medical Dismisses Patent Case against Masimo and Cercacor
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
10. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
11. Broad Patent Protection Granted for iBio Immunomodulator
Post Your Comments:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
Breaking Medicine News(10 mins):